Pfizer’s Revenue by Segment (2016-2022)

You need Pro Plan to access KPI data.

Get 60% off on Pro

Discount ends in:

00
Days
00
Hours
00
Mins.
00
Seconds

.

About

This statistic highlights Pfizer’s Revenue by Segment from 2016 onwards, split between Biopharma, Essential Health, Innovative Health, and Upjohn.
Subscribe to Pro or Enterprise plans to unlock this feature.
More information

Subscribe to Pro or Enterprise plans to unlock this feature.

Contact the Analyst

Subscribe to Pro or Enterprise plans to unlock this feature.

Become a smarter investor today.

Access Business Quant for as low as $19/month

Become a smarter investor today.

Access KPIs & Segment Financials on US stocks

This statistic highlights Pfizer’s Revenue by Segment from 2016 onwards, split between Biopharma, Essential Health, Innovative Health, and Upjohn.

Pfizer’s Revenue by Segment

Pfizer is now operating with a single segment since Q4 2020. This segment is engaged in research, innovation, development, manufacturing, marketing, sales, and distribution of biopharmaceutical products around the globe. Distribution, selling, and marketing of Pfizer’s products are done by regional commercial organizations.

Segment Revenue in Q1 2019 Revenue in Q1 2020 YOY Growth in Q1 2020 Revenue Share in Q1 2020
Biopharma $9.19 $10.01 8.95% 83.19%

(All figures in billion, except percentages)

Pfizer has a massive market capitalization of $0.2 trillion. Its 1-year revenue growth is 16.6%, while the industry average is at 12.2%. Pfizer’s 3-year revenue growth is – 5.5% which is a poor sign of fundamentals.

In December 2018, GSK’s consumer healthcare business obtained Consumer Healthcare for the formation of a consumer healthcare Joint Venture where Pfizer holds a 32% equity stake.

Biopharma

  • Array BioPharma was founded in 1998 by Dr. Tony Piscopio, Dr. Kevin Koch, Dr. David Snitman, and Dr. K.C. Nicolaou.
  • Pfizer acquired Array BioPharma Inc. in June 2019. It especially focuses on oncology meditation.
  • Biopharma is an innovative medicines business that includes six business units – Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines, and Internal Medicine.
  • Biopharma strengthens Pfizer’s oncology category. Pfizer expects a long-term growth trajectory through biopharma’s new medicines.
  • Biopharma’s revenue increased from $9.19 billion in Q1 2019 to $10.01 billion in Q1 2020 reflecting 8.95% year-over-year growth. Biopharma’s sales contributed 81.19% towards Pfizer’s top line in Q1 2020.

Essential Health 

  • Pfizer Essential Health included legacy brands that have already lost or about to lose their market in developing and emerging markets.
  • Essential Health also had an R&D organization and contract manufacturing business.
  • Some of the leading brands included in Essential health were Lyrica, Celebrex, Viagra, Lipitor, and Norvasc.
  • Essential Health generated a revenue of $5.08 million in Q1 2018. However, its operations were discontinued after Q4 2018.

Innovative Health

  • Pfizer’s innovative health focused on developing medicines, vaccines, and consumer healthcare products.
  • Pfizer’s Innovative Health included 6 business groups – Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Diseases, and Vaccines.
  • Some of the leading brands included in Innovative Health were Lyrica, Enbrel, Ibrance, and Xtandi.
  • Pfizer Innovative Health’s revenue increased from $7.42 billion in Q1 2017 to $7.83 billion in Q1 2018, reflecting a 5.58% increase.
  • Even Innovative Health’s operations were discontinued after Q4 2018 like Essential Health.

Upjohn

  • Upjohn was a pharmaceutical manufacturing firm, founded by Dr. William Upohn in 1886. Upjohn merged with Pharmacia AB formed Pharmacia and Upjohn in 1995. Pfizer owned Upjohn from 2015 until 2020.
  • Upjohn was an off-patent branded and generic established medicines business.
  •  Upjohn generated revenue of $2.02 billion in Q1 2020, marking a 34.24% year-over-year decrease. Upjohn’s sales accounted for 16.81% of Pfizer’s overall revenue in Q1 2020.
  • On 16th November 2020, Pfizer merged Upjohn with Mylan and formed Viatris through a Reverse Morris Trust structure. Thus, in Q4 2020, the financial results of Upjohn were not reflected as its operations were discontinued.

Covid-19 Vaccine

Pfizer partnered with BioNTech in March 2019, to develop the Covid-19 mRNA vaccine. Pfizer invested around $2 billion in developing this product. The vaccines were ready for the testing phase in May 2020, with four different variations. On 9th November 2020, Pfizer’s vaccine was tested on 43,500 people and the vaccine came out to be 90% effective. However, efficacy was updated to 95% in the next week. As of May 2021, Pfizer and BioNTech manufacture a minimum of 430 million doses distributing to 91 different countries and territories.

Company Overview 

Pfizer Inc. is a research-based multinational pharmaceutical and biotechnology corporation founded in 1849 by Charles Pfizer and Charles Erhart. The company is headquartered in Manhattan, New York City. Pfizer started its journey by producing antiparasitic and santonin. Further, in the 1880s Pfizer’s production of citric acid bring them a huge success.  As of 1906, Pfizer’s sales exceeded $3 million. As a result of World War 1, there was a shortage of calcium citrate, a major component for citric acid production. However, the company came across an alternative for the production of citric acid and expertise in fermentation technology. In addition, these skills were used for the mass production of Penicillin during world war 2. Penicillin was used to treat injured soldiers.

The company was incorporated in Delaware in June 1942. Pfizer’s major revenue comes from the manufacturing and selling of biopharmaceutical products. On the other hand, Pfizer also generates revenue through alliance agreements. Pfizer is famous for its medicines and vaccines. Pfizer introduced a new logo on 5th January 2021.

Did you like Pfizer’s Revenue by Segment statistic?

Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.

You can also get started for free.

Read more

Our Plans

Always know what you’ll pay. No hidden costs or surprises.

  • Annual
  • Monthly

Basic

$0
per month

Get to know us

  • Access basic data
  • No credit card required
Start for Free

60% discount until September 30

Pro

$19
per month*

For serious investing

  • Granular KPI data
  • Stock research tools
  • Industry data & tools
Buy Now

Enterprise

$99
per month, onwards*

For tailored workflows

  • All of Pro plan
  • Custom built features
Contact Us

* Billed annually, local taxes extra. 

Basic

$0
per month

Get to know us

  • Access basic data
  • No credit card required
Start for Free

60% discount on Annual plan

Pro

$49
per month*

For serious investing

  • Granular KPI data
  • Stock research tools
  • Industry data & tools
Buy Now

Enterprise

$99
per month, onwards*

For tailored workflows

  • All of Pro plan
  • Custom built features
Contact Us

* Local taxes extra. 

BQ Star Yellow 60%

Get Pro for 60% off

  • Access all features immediately
  • Datasets updated every day
  • Export data in CSV and XLSX formats

Offer Ends In

Starting from $49 $19 / month

.